Cargando…
The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation
In recent years many articles have underlined the key role of nanovesicles, i.e., exosomes, as information carriers among biological systems including cancer. Tumor-derived exosomes (TEXs) are key players in the dynamic crosstalk between cancer cells and the microenvironment while promote immune sys...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979514/ https://www.ncbi.nlm.nih.gov/pubmed/29652798 http://dx.doi.org/10.3390/ijms19041183 |
_version_ | 1783327714973843456 |
---|---|
author | Alfonsi, Romina Grassi, Ludovica Signore, Michele Bonci, Désirée |
author_facet | Alfonsi, Romina Grassi, Ludovica Signore, Michele Bonci, Désirée |
author_sort | Alfonsi, Romina |
collection | PubMed |
description | In recent years many articles have underlined the key role of nanovesicles, i.e., exosomes, as information carriers among biological systems including cancer. Tumor-derived exosomes (TEXs) are key players in the dynamic crosstalk between cancer cells and the microenvironment while promote immune system control evasion. In fact, tumors are undoubtedly capable of silencing the immune response through multiple mechanisms, including the release of exosomes. TEXs have been shown to boost tumor growth and promote progression and metastatic spreading via suppression or stimulation of the immune response towards cancer cells. The advantage of immunotherapeutic treatment alone over combining immuno- and conventional therapy is currently debated. Understanding the role of tumor exosome-cargo is of crucial importance for our full comprehension of neoplastic immonosuppression and for the construction of novel therapies and vaccines based on (nano-) vesicles. Furthermore, to devise new anti-cancer approaches, diverse groups investigated the possibility of engineering TEXs by conditioning cancer cells’ own cargo. In this review, we summarize the state of art of TEX-based immunomodulation with a particular focus on the molecular function of non-coding family genes, microRNAs. Finally, we will report on recent efforts in the study of potential applications of engineered exosomes in cancer immunotherapy. |
format | Online Article Text |
id | pubmed-5979514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-59795142018-06-10 The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation Alfonsi, Romina Grassi, Ludovica Signore, Michele Bonci, Désirée Int J Mol Sci Review In recent years many articles have underlined the key role of nanovesicles, i.e., exosomes, as information carriers among biological systems including cancer. Tumor-derived exosomes (TEXs) are key players in the dynamic crosstalk between cancer cells and the microenvironment while promote immune system control evasion. In fact, tumors are undoubtedly capable of silencing the immune response through multiple mechanisms, including the release of exosomes. TEXs have been shown to boost tumor growth and promote progression and metastatic spreading via suppression or stimulation of the immune response towards cancer cells. The advantage of immunotherapeutic treatment alone over combining immuno- and conventional therapy is currently debated. Understanding the role of tumor exosome-cargo is of crucial importance for our full comprehension of neoplastic immonosuppression and for the construction of novel therapies and vaccines based on (nano-) vesicles. Furthermore, to devise new anti-cancer approaches, diverse groups investigated the possibility of engineering TEXs by conditioning cancer cells’ own cargo. In this review, we summarize the state of art of TEX-based immunomodulation with a particular focus on the molecular function of non-coding family genes, microRNAs. Finally, we will report on recent efforts in the study of potential applications of engineered exosomes in cancer immunotherapy. MDPI 2018-04-13 /pmc/articles/PMC5979514/ /pubmed/29652798 http://dx.doi.org/10.3390/ijms19041183 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Alfonsi, Romina Grassi, Ludovica Signore, Michele Bonci, Désirée The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation |
title | The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation |
title_full | The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation |
title_fullStr | The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation |
title_full_unstemmed | The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation |
title_short | The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation |
title_sort | double face of exosome-carried micrornas in cancer immunomodulation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979514/ https://www.ncbi.nlm.nih.gov/pubmed/29652798 http://dx.doi.org/10.3390/ijms19041183 |
work_keys_str_mv | AT alfonsiromina thedoublefaceofexosomecarriedmicrornasincancerimmunomodulation AT grassiludovica thedoublefaceofexosomecarriedmicrornasincancerimmunomodulation AT signoremichele thedoublefaceofexosomecarriedmicrornasincancerimmunomodulation AT boncidesiree thedoublefaceofexosomecarriedmicrornasincancerimmunomodulation AT alfonsiromina doublefaceofexosomecarriedmicrornasincancerimmunomodulation AT grassiludovica doublefaceofexosomecarriedmicrornasincancerimmunomodulation AT signoremichele doublefaceofexosomecarriedmicrornasincancerimmunomodulation AT boncidesiree doublefaceofexosomecarriedmicrornasincancerimmunomodulation |